Increasing the Tumoricidal Activity of Daunomycin-pHPMA Conjugates Using Vitamin B12 as a Targeting Agent

Russell‐Jones, Gregory; McTavish, Kirsten J.; McEwan, John; Thurmond, None Bruce

doi:10.6000/1929-2279.2012.01.02.6

Cited by 6 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Folic acid targeted daunomycin-HPMA conjugates were found to increase both the number of survivors and the survival time of tumor-bearing mice. The data indicate that folic acid may be highly effective in enhancing the efficacy of other polymer-bound cytotoxins [34].…”

Section: Specific Receptor Targetingmentioning

confidence: 93%

Nanotechnology in Cancer Drug Delivery and Selective Targeting

Sutradhar

Amin

2014

ISRN Nanotechnology

250

142

View full text Add to dashboard Cite

Nanoparticles are rapidly being developed and trialed to overcome several limitations of traditional drug delivery systems and are coming up as a distinct therapeutics for cancer treatment. Conventional chemotherapeutics possess some serious side effects including damage of the immune system and other organs with rapidly proliferating cells due to nonspecific targeting, lack of solubility, and inability to enter the core of the tumors resulting in impaired treatment with reduced dose and with low survival rate. Nanotechnology has provided the opportunity to get direct access of the cancerous cells selectively with increased drug localization and cellular uptake. Nanoparticles can be programmed for recognizing the cancerous cells and giving selective and accurate drug delivery avoiding interaction with the healthy cells. This review focuses on cell recognizing ability of nanoparticles by various strategies having unique identifying properties that distinguish them from previous anticancer therapies. It also discusses specific drug delivery by nanoparticles inside the cells illustrating many successful researches and how nanoparticles remove the side effects of conventional therapies with tailored cancer treatment.

show abstract

Section: Specific Receptor Targetingmentioning

confidence: 93%

Nanotechnology in Cancer Drug Delivery and Selective Targeting

Sutradhar

Amin

2014

ISRN Nanotechnology

250

142

View full text Add to dashboard Cite

show abstract

“…One example which has been quite promising, in both in vitro and in vivo experiments, is the interaction between the folate receptor, overexpressed in many tumor cells but absent in most human tissues, and the complementary folic acid ligand, covalently conjugated onto nanoparticles. The nanoparticle−ligand conjugates exhibited enhanced and selective targeting to folate receptor-positive cells in vitro 17 and significant tumor suppression in vivo. 18 This nanocarrier is currently in the clinical trial stage of development.…”

Section: Drug Delivery From Nonspecific Targeting To Selective Targetingmentioning

confidence: 99%

Evolution of Nanocarrier Drug-Delivery Systems and Recent Advancements in Covalent Organic Framework–Drug Systems

Scicluna

Vella‐Żarb

2020

ACS Appl. Nano Mater.

140

View full text Add to dashboard Cite

Nanotechnology has been actively employed in the development of drug-delivery systems overcoming the limitations of conventional carriers. In nanomedicine, the ultimate goal is to design and develop a system for the prevention, diagnosis, control, and treatment of debilitating diseases. Nanoparticles can be designed and programmed to have unique physical properties, in order to protect the loaded drug against degradation and/or denaturation by natural processes inside the body, while selectively delivering it to target areas having the desired cells. This effectively minimizes the active pharmaceutical ingredient's (API's) systemic exposure and, consequently, the occurrence of adverse side effects. The enhanced control on the distribution and release of the entrapped drug molecules, through active targeting and controlledrelease technology, allows for their increased and accurate cellular uptake. In this review, we summarize the development of nanobased drug-delivery systems, with a focus on smart systems and the necessary characteristics required for the optimal drug nanocarrier. The recently developed class of crystalline porous polymers, covalent organic frameworks (COFs), possesses a unique combination of characteristics including permanent yet tunable discrete pores having high surface areas and large volumes, making them intrinsically designed to accommodate APIs as guest molecules in their highly ordered pores. The extensive synthetic and molecular design flexibility of COFs allows the structural control and tuning of their morphology, regularity, atomic connectivity, and porosity, for this specific application. Through an overview of the recent advancements in the novel application of metal− organic frameworks (MOFs) and COFs as drug nanocarriers, we demonstrate this promising alternative route to effectively increase the drug solubility and enhance the limited loading capacity and release control of nanoparticle systems. Since the first reported COF nanocarriers in 2011 as passive targeting drug-delivery systems, this application of COFs has been slowly gaining traction, with increasingly complex COF nanocarrier drug-delivery systems reported in the past year.

show abstract